APIs and Excipients

Novasep to Invest $7.6 million to Expand API Manufacturing Workshop Capacity

November 11, 2020

Construction on the workshop is currently underway with plans for it to be fully operational by the end of 2021.

Understanding Excipient Quality and Impact on Formulation

November 04, 2020

At the 2020 Bio/Pharma Virtual Congress, experts discuss the importance of characterizing excipients to ensure quality, safety, and effective performance.

Lonza to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination

November 03, 2020

The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19, at Lonza's Portsmouth, NH site.

Fermentation Finds Fans in Small-Molecule API Synthesis

November 03, 2020

Biological and analytical advances enable modern fermentation processes to deliver safe and effective next-generation medicines.

Masking Taste: A Key Attribute to Success

October 03, 2020

Taste-masking can be of significant importance in ensuring success of a drug product, particularly those targeted to pediatric or geriatric populations.

Factoring Stability in the Biologic Drug Mix

October 03, 2020

Excipients must be carefully chosen to ensure optimum protection for vaccines and live biotherapeutic products.

Modernizing Bioprocessing for Gene Therapy Viral Vectors

October 03, 2020

The manufacture of gene therapy vectors is shifting to more modern technologies.

Cellular and Gene Therapies Face a Manufacturing Capacity Crunch

October 02, 2020

Cellular and gene therapy fields are currently on track for, if not already experiencing, a serious capacity crunch.

Orgenesis to Acquire Koligo Therapeutics

October 01, 2020

The acquisition will support the accelerated commercialization of Kyslecel (autologous pancreatic islets), Koligo’s personalized cell therapy for treating pancreatitis.

Roche Closes Agreement with Inflazome for $450 Million

September 21, 2020

Roche will gain full rights to Inflazome’s portfolio which includes clinical and preclinical orally available small molecule NLRP3 inhibitors.